Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2379]

Hemcare - multiple myeloma learning programme

Erik Aerts - President of HNHCP, Winterthur, Switzerland

Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )

Extended followup indicates daratumumab with bortezomib and dexamethasone for...

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Impact of mutational profile at diagnosis for MDS/CML

Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy

The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

Carfilzomib combinations in ENDEAVOR and FORTE

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Deep molecular response to gilteritinib in CHRYSALIS trial

Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern...

Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

More from ecancer